Company Profile

Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company's licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-08-25	Apexigen, Inc.(NasdaqCM:APGN) dropped from S&P TMI Index	CI
23-08-23	Pyxis Oncology Completes Acquisition of Apexigen	MT
23-08-23	Apexigen, Inc.(NasdaqCM:APGN) dropped from NASDAQ Composite Index	CI
23-08-22	Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	CI
23-08-10	Apexigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-06-03	Apexigen, Inc. Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology 2023 Annual Meeting	CI
23-05-24	Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	MT
23-05-24	Apexigen, Inc., Pyxis Oncology, Inc. - M&A Call
23-05-24	US Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes Release	MT
23-05-24	Top Premarket Gainers	MT
23-05-24	Pyxis Oncology to Acquire Apexigen in $16 Million All-Stock Deal	MT
23-05-16	EF Hutton Adjusts Price Target on Apexigen to $5 From $8, Maintains Buy Rating	MT
23-05-15	Apexigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

23-05-16	EF Hutton Adjusts Price Target on Apexigen to $5 From $8, Maintains Buy Rating	MT
23-01-24	Roth Capital Reinstates Apexigen at Buy Rating With $15 Price Target	MT
23-01-05	EF Hutton Starts Apexigen at Buy With $8 Price Target	MT
22-10-17	Roth Capital Starts Apexigen at Buy with $13 Price Target	MT

23-08-10	APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN	BU
23-06-03	Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting	AQ
23-05-30	APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN	BU
23-05-24	Pyxis Oncology to Acquire Apexigen	AQ
23-04-12	APEXIGEN, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ

Manager	Title	Age	Since
David Ho PRN	Corporate Officer/Principal	73	-
Ronald Levy PRN	Corporate Officer/Principal	-	-
Brian Daniels PRN	Corporate Officer/Principal	67	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-08-22	Scott Smith	Issuer sale	Director	134,084	0.5396%
23-08-22	Herbert Cross	Issuer sale	Director	134,084	0.5396%
23-08-22	Gordon Ringold	Issuer sale	Director	149,084	0.5999%

Apexigen, Inc. Stock

Stocks

APGN

US03759B1026

Biotechnology & Medical Research

Latest news : Apexigen, Inc.

Analysts' recommendations: Apexigen, Inc.

Press Releases: Apexigen, Inc.

Quotes and Performance

Managers and Directors: Apexigen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APEXIGEN, INC.	-6.68%	-10.97%	-	-	9.57M
ARGENX SE	+2.14%	+7.57%	+74.46%	+123.84%	56.65B
WUXI APPTEC CO., LTD.	-0.49%	+6.98%	+62.88%	+67.95%	47.49B
BIONTECH SE	+1.12%	+1.70%	-11.64%	-15.05%	22.81B
INSMED INCORPORATED	+3.36%	+4.96%	-4.89%	+402.30%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+1.30%	+0.71%	+29.21%	-17.51%	16.12B
GENMAB A/S	+3.20%	+9.80%	+26.27%	-34.74%	15.56B
EXELIXIS, INC.	+0.59%	-0.98%	+18.95%	+159.77%	12.91B
PHARMAESSENTIA CORPORATION	0.00%	+15.02%	+133.24%	+273.89%	12.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.43%	-5.06%	+23.53%	-	11.67B
Average	+0.61%	+1.74%	+39.11%	+120.06%	24.16B
Weighted average by Cap.	+1.35%	+3.17%	+45.74%	+113.04%